g****e
发帖数: 1426 | 1 From my blog:
http://www.mitbbs.com/pc/pccon_12673_256059.html
TSRX -- current at 4.45
It is still in down trend, it seems will go to 4. Once the share price
stable, will load.
Catalyst event:
"As with our ESTABLISH 1 study, ESTABLISH 2 was designed to prepare
tedizolid for
registration globally by capturing both the new and former FDA endpoints as
well as the
European endpoints for ABSSSI," said Jeffrey Stein, Ph.D., President and
Chief
Executive Officer at Trius. "We remain on schedule to report top-line
results from this
study in early 2013. The tedizolid clinical program reflects our commitment
to bring safe,
well-tolerated and convenient therapies to people with life-threatening
infections."
Target: $7 in 2 months | g****e
发帖数: 1426 | 2 TRSX tedizolid is structural similar to PFE billion drug Zyvox, but more
safer, potent and more effective.
According to clinical trial agency, its second phase 3 trial will be
complete in Feb 2013, so result will be available in 1Q next year (late Feb
or early March).
http://clinicaltrials.gov/ct2/show/NCT01421511?term=Trius&rank=
TRSX has cash 70m, 0 debt, while current market cap is only about 200m.
TRSX is a stock can be held strong and long into 2013!! |
|
